Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can head position and cooling boost brain recovery after cardiac arrest?

NCT ID NCT07769086

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether specific care strategies used in the intensive care unit after cardiac arrest can improve neurological recovery and survival. Adults who remain comatose after their heartbeat is restored will be cared for using either head elevation or a near-supine position, and either targeted cooling or fever prevention. The study compares these approaches to see which may lead to better brain function and quality of life at 30 and 90 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Head positioning (head elevation vs. near-supine) and temperature control (targeted hypothermia vs. normothermia/fever prevention) during post-cardiac arrest intensive care
What this could lead to
If successful, this could identify simple, low-cost care strategies that improve brain recovery and survival for people who remain comatose after cardiac arrest.
What could go wrong
The trial is early and uses hospital-level randomization, so results may be influenced by differences in care quality. The interventions may not improve outcomes and could carry risks like complications from cooling or positioning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Master Platform Eligibility: * Adult patients aged 18 years or older * Return of spontaneous circulation after cardiac arrest * Persistent coma after return of spontaneous circulation (GCS motor score \<6) * Requirement for intensive care management Head Positioning Domain Eligibility: * Non-traumatic out-of-hospital or in-hospital cardiac arrest * Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable) Temperature Control Domain Eligibility: * Initial non-shockable cardiac arrest rhythm * Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable) * Ability to initiate temperature control therapy within 240 minutes after return of spontaneous circulation Exclusion Criteria: Master Platform Exclusion: * Refusal of intensive care management * Extracorporeal cardiopulmonary resuscitation (ECPR) * Pregnancy or possible pregnancy * Cardiac arrest due to intracranial hemorrhage, subarachnoid hemorrhage, cerebral infarction, acute aortic dissection, or terminal cancer (including suspected cases) * Severe chronic obstructive pulmonary disease requiring home oxygen therapy * Poor pre-arrest neurological function (CPC 3-4) or poor overall functional status (OPC 3-4) * Pre-existing do-not-attempt-resuscitation (DNAR) order * Expected early death * Inability to obtain consent from a legally acceptable representative or the participant * Enrollment judged inappropriate by the investigator Head Positioning Domain Exclusion: * Body temperature \<30°C on hospital arrival * Refusal of consent for participation in the head positioning domain * Enrollment judged inappropriate by the investigator * Patients using Impella® (a percutaneous mechanical circulatory support catheter) at the time of ICU admission * Patients using an intra-aortic balloon pump (IABP) at the time of ICU admission * Patients for whom feedback-controlled device-based temperature management or fever prevention is not being performed and is not planned at the time of ICU admission Temperature Control Domain Exclusion: * rCAST \<4.5 * rCAST ≥17.0 * Traumatic cardiac arrest * Body temperature \<30°C on hospital arrival * Refusal of consent for participation in the temperature control domain * Enrollment judged inappropriate by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac arrest (CA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aso Iizuka Hospital

    Iizuka, Fukuoka, 8208505, Japan

  • Chiba Kaihin Municipal Hospital

    Chiba, Chiba, 2610012, Japan

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, 7348551, Japan

  • Hyogo Emergency Medical Center

    Kobe, Hyōgo, 651-0073, Japan

  • Kagawa University Hospital

    Kita-gun, Kagawa-ken, 761-0701, Japan

  • Kyoto Katsura Hospital

    Kyoto, Kyoto, 6158256, Japan

  • Musashino Red Cross Hospital

    Musashino, Tokyo, 1800023, Japan

  • National Hospital Organization Sendai Medical Center

    Sendai, Miyagi, 9838520, Japan

  • Nippon medical school hospital

    Bunkyō-Ku, Tokyo, 113-8603, Japan

  • Okayama University Hospital

    Okayama, Okayama-ken, 7008558, Japan

  • TMG Asaka Medical Center

    Asaka, Saitama, 3510023, Japan

  • Tokyo Metropolitan Bokutoh Hospital

    Sumida-ku, Tokyo, 1308575, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.